Affimed to Present at the Jefferies Virtual Healthcare Conference 2021
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Affimed N.V. (Nasdaq: AFMD) announced that its CEO, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:30 a.m. Eastern Time.
A live webcast can be accessed on Affimed’s website, with an archived replay available for 30 days post-event.
Affimed is focused on immuno-oncology and utilizes its proprietary ROCK® platform to harness the innate immune system in cancer treatment, developing innovative therapies to target various tumors.
Details
News Market Reaction – AFMD
The recorded move for AFMD in the trading session of this news was +1.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:30 a.m. Eastern Time.
A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on Affimed’s website for 30 days after the call.
For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.
Affimed Investor Contact
Alexander Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.